Estimation of Liver and Kidney Biomarkers for People During Their Infection with SARA-COV-2 (COVID-19) Virus in Nineveh Governorate

Abstract

SARS-CoV-2 harms organs, kidneys, and liver. Most seriously ill COVID-19 patients had liver and renal failure. Our study examined liver and renal function in moderate and severe COVID-19 individuals. The study comprised 56 COVID-19 patients in Nineveh Governorate (32 men, 24 women). Their ages ranged between (30 and 65) years. These patients were divided into two groups according to the severity of the disease. The first group included 25 patients with mild disease, and the second included 31 patients with severe disease. Liver and kidney function and other biomarkers were measured. The results showed that all severe patients had a significant difference in alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin urea, and creatinine compared with mild patients (all p<0.0001 except creatinine, p= 0.014). Moreover, patients with severe disease were older than those with mild disease. Males were also more affected by Covid-19. We conclude that patients with COVID-19, especially those with severe disease, suffer from liver and kidney dysfunction. Therefore, the severity of this disease can be predicted by examining the levels of ALT, AST, bilirubin, urea, and creatinine. Moreover, the progression from mild to severe disease in COVID-19 patients can be predicted by the combination of ALT, AST, bilirubin, urea, and creatinine levels.